ARTICLE | Clinical News
SYN-010: Phase II started
October 26, 2015 7:00 AM UTC
Synthetic began an open-label, U.S. Phase II extension trial to evaluate 42 mg oral SYN-010 once daily for about 2 months in about 60 patients who completed the Phase II SB-2-010-001 trial. Top-line d...